FEMERISGenesisbiotech Group
Home About Us Collaborations Products Research Publications

Products

Clinical Diagnostic Tests

FEMERIS has created a product development program using guidelines from CLIA and CLSI with the goal to efficiently bring sensitive and specific testing into the clinical diagnostic lab. Our product development begins with investment in basic research to identify and validate potential biomarkers. The next phase includes applied research to translate these findings into useable diagnostic tools. We then test our diagnostic assays in a prospective clinical trial before final transfer to our clinical diagnostic laboratory or other partners for commercialization.

 

Patents

Gygax SE, Overmyer CL, Desalvia LA, Adelson ME, Mordechai E. A Method of Determining Types I, II, III, IV, and V Methicillin-Resistant Staphylococcus aureus (MRSA) in a Biological Sample. Patent No. US 8,715,936 issued May 6, 2014.

Gygax SE, Vermitsky J-P, Chadwick SG, Self MJ, Mordechai E, Adelson ME. A Method for Determining Azole Resistance in Candida glabrata. Patent No. US 8,021,846 issued September 20, 2011.

Hilbert DW, Gygax SE, Adelson ME, Mordechai E, Schuyler JA, Paulish-Miller T. (2013) Metronidazole Resistance in Trichomonas vaginalis and Single Nucleotide Polymorphisms. US Patent (USPTO Pub. No.: US 2013/0130253)

Balashov S, Mordechai E, Adelson ME, Gygax SE. (2012) Antibiotic Resistance Profile for Neisseria gonorrhoeae and Use of Same in Diagnosis and Treatment of gonorrhea. US Patent (USPTO Pub. No.: US 2012/0071336)

Gygax SE, Chadwick SG, Prasad A, Adelson ME, Mordechai E. (2012) Novel Single Nucleotide Polymorphisms and Community-Associated Methicillin Resistant Staphylococcus aureus. US Patent (USPTO Pub. No.: US 2012/0009572)

Gygax SE, Prasad A, Adelson ME, Mordechai E. (2010) Detection of Penicillin Tolerance in Group B Streptococcus: Single Nucleotide Polymorphisms in Penicillin Binding Protein 4. US Patent (USPTO Pub. No.: 2010/0028884).

Latest News

10/2015 - FEMERIS publication: Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. in Diagn Microbiol Infect Dis..

9/2015 - FEMERIS publication: Schuyler JA, Chadwick SG, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate. in Genome Announc..

9/2015 - FEMERIS publication: Schuyler JA, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome Sequence of a Metronidazole-Susceptible Atopobium vaginae Isolate. in Genome Announc..

7/2014 - Genesis Biotechnology Group (GBG) sponsored a two-day symposium on June 18th and 19th entitled “The Vaginal Microbiome and Bacterial Vaginosis.” Read Full Story

7/2014 - FEMERIS publication: Smith WL, Hedges S, Mordechai E, Adelson ME, Trama J, Gygax SE, Kaunitz AK, Hilbert DW. Cervical and vaginal flora is highly concordant with respect to bacterial vaginosis-associated organisms and commensal lactobacillus species in reproductive-aged women. J. Clin. Micrbiol. In Press.

7/2014 - FEMERIS publication: Whaley S, Caudle K, Vermitsky J-P, Chadwick SG, Toner G, Barker K, Gygax SE, Rogers PD. UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob. Agents Chemother. In Press.

10/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Novel antifungal drug discovery based on targeting pathways regulating the fungal-conserved Upc2 transcription factor” accepted into the journal Antimicrobial Agents and Chemotherapy.

9/2013 - FEMERIS Director Dr. Scott Gygax presented work done by Research Associate Sean Chadwick in a poster entitled “Disruption of Gardnerella vaginalis biofilms with clindamycin and metronidazole” at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colorado.

8/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1” accepted into the journal Antimicrobial Agents and Chemotherapy.

5/2013 - FEMERIS Research Associates, Lamar Smith and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “Detection of epidemic USA300 community-associated MRSA strains using a single allele-specific PCR targeting a novel polymorphism of Staphylococcus aureus pbp3” accepted into the Journal of Clinical Microbiology.

1/2013 - FEMERIS Director Dr. Scott Gygax had a manuscript entitled, “Mixed vaginitis- more than coinfection and with therapeutic implications” accepted into the journal Current Infectious Disease Reports.

1/2013 - FEMERIS Research Associates, Jessica Schuyler and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “X-Plate Technology™: A new method for detecting fluconazole resistance in Candida species” accepted into the Journal of Medical Microbiology.